Ghobrial Irene M, Leleu Xavier, Hatjiharissi Evdoxia, Hideshima Teru, Mitsiades Constantine, Schlossman Robert, Anderson Kenneth C, Richardson Paul
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA.
Expert Opin Emerg Drugs. 2007 Mar;12(1):155-63. doi: 10.1517/14728214.12.1.155.
The treatment of multiple myeloma has seen significant changes from the time of the initial use of cytotoxic agents such as melphalan, to the introduction of high-dose chemotherapy and stem cell transplantation, and most recently the era of novel targeted agents. These new drugs have rapidly become the mainstay of therapy of this disease and transformed the treatment paradigm, leading to improvements in survival and quality of life. Existing therapeutic options include agents such as thalidomide, bortezomib and lenalidomide, either used alone or in combination with standard agents, including glucocorticoids, and in conjunction with high-dose chemotherapy supported with stem cell transplantation. Several other targeted agents have demonstrated exciting preclinical activity, and are presently being tested in early Phase I and II clinical trials. This review summarizes the role of novel therapeutic agents in multiple myeloma, and the promising effect of multiple new agents in development.
从最初使用诸如美法仑等细胞毒性药物，到引入大剂量化疗和干细胞移植，以及最近进入新型靶向药物时代，多发性骨髓瘤的治疗发生了显著变化。这些新药迅速成为该疾病治疗的主要手段，并改变了治疗模式，从而提高了生存率和生活质量。现有的治疗选择包括沙利度胺、硼替佐米和来那度胺等药物，它们可单独使用，或与包括糖皮质激素在内的标准药物联合使用，并结合干细胞移植支持的大剂量化疗。其他几种靶向药物已显示出令人兴奋的临床前活性，目前正在进行I期和II期早期临床试验。本综述总结了新型治疗药物在多发性骨髓瘤中的作用，以及多种正在研发的新药的前景。
